Repligen corp stock.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ...

Dec 4, 2023 · × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE RGEN Repligen Corp. 161.78 1.57 ( 0.98%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.When you start a small business, you’ll have many decisions to make. The process involves everything from choosing a business model and designing your marketing materials to hiring employees and setting prices.11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price.

UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.

In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...

The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...RGEN | AI Stock Analysis for Repligen Corp. RGEN Including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and More.Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Item 7.01 Regulation FD Disclosure. On April 12, 2023, Repligen Corporation (the "Company") made available an Investor Presentation relating to the FlexBiosys Transaction described in Item 8.01 of this 8-K. A copy of this Investor Presentation is attached to this Current Report on Form 8-K and furnished as Exhibit 99.1.Stock Exchange NASDAQ Ticker Symbol RGEN Full Company Profile Financial Performance In 2022, Repligen's revenue was $801.54 million, an increase of …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2] 305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Why Repligen Corp’s (RGEN) Stock Is Down 4.07% As of Thursday, September 21, Repligen Corp’s RGEN share price has dipped by 4.07%, which has investors questioning if this is right time to buy. Jenna Brashear. Price Why Repligen Corp’s (RGEN) Stock Is Up 4.03%4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Investors. These pages provide visibility to Repligen news, SEC filings, financial and other information that may factor into an investment decision. We welcome your questions or comments. [email protected]. On October 17, 2023, Repligen Corp (RGEN) stock showed promising performances, with a median target price forecast of $195.00 by 13 analysts. This represents a potential increase of 33.96% from the last recorded price of $145.57. The high estimate for the stock price is $240.00, while the low estimate is $165.00.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.3% in the past year. Currently, Repligen Corp’s price-earnings ratio is 64.0. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …Dec 2, 2023 · Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis. Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions.

Company profile page for Repligen Corp including stock price, company news, press releases, executives, board members, and contact information

The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...

Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Repligen Corp stock has a Value Score of 4, Momentum Score of 73 and Quality Score of 72. Comparing Becton Dickinson and Co and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Sep 15, 2022 09:19AM EDT. Today we're going to take a look at the well-established Repligen Corporation (NASDAQ:RGEN). The company's stock saw a significant share price rise of over 20% in the ...Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%.Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Repligen Corp’s ( RGEN) price is currently down 4.66% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $160.14. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 37.23%.Repligen Corporation Stock price Equities RGEN US7599161095 Medical Equipment, Supplies & Distribution Summary Quotes Charts News Ratings Calendar …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. ... Repligen (RGEN) Frequently Asked Questions. What does Repligen do? Repligen Corp is a global life sciences company. It develops and commercializes innovative ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued.

Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The latest Repligen stock prices, stock quotes, news, and RGEN history to help you invest and trade smarter. A vertical stack of three evenly spaced horizontal lines. ... Repligen Corp. is a ...Instagram:https://instagram. american electric stockdread mar i tourpurchase bitcoins with venmojfk coin value Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you. emerson electric company stockdhhorton Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock... online bank account instant debit card On Friday, Repligen Corp (RGEN:NSQ) closed at 161.78, -19.50% below its 52-week high of 200.98, set on Feb 16, 2023. Data delayed at least 15 minutes, as of Nov 24 2023 18:00 GMT. Latest Repligen Corp (RGEN:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.On September 12, 2023, Repligen Corp (HONE) stock performed well, with a median target price forecast of $200.00. The consensus among the 13 polled investment analysts is to buy stock in Repligen Corp. Repligen Corp is expected to release its current quarter earnings report on October 26. The company is projected to have earnings per share of ...